 Shares of CymaBay Therapeutics NASDAQ: CBAY have climbed nearly 143 since last week after it got great news about its orphan drug, seladelpar. A phase 2B trial for the drug to see how it did against nonalcoholic steatohepatitis NASH, or liver inflammation not caused by alcohol had been sidelined by the Newark, Calif., clinical-stage biopharmaceutical company since November due to safety concerns after study pathologists found tissue damage in the livers of participants. Last week, however, the company announced that a panel of independent experts unanimously overturned earlier findings that seladelpar caused liver damage. 